A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma

Annals of Hematology

Volumn 89, Issue 11, 2010, Pages 1107-1113

  Fang, Cheng ^a   Xu, Wei ^a   Li, Jian Yong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diffuse large B cell lymphoma; Meta analysis; Review; Rituximab; Subtypes

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; PREDNISONE; RITUXIMAB; THERARUBICIN; UNCLASSIFIED DRUG; VINCRISTINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CLASSIFICATION; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; GERMINAL CENTER; HUMAN; LARGE CELL LYMPHOMA; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; ADULT; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PROCEDURES; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; SURVIVAL RATE; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, MURINE-DERIVED;

EID: 77956949925     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0990-5     Document Type: Article

References (28)

1. LM Morton SS Wang SS Devesa P Hartge DD Weisenburger MS Linet 2006 Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood 107 265 276 1:CAS:528:DC%2BD28XhsVGlsg%3D%3D 10.1182/blood-2005-06-2508 16150940 (Pubitemid 43053551)
2. Anonymous (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918
3. B Coiffier 2001 Diffuse large cell lymphoma Curr Opin Oncol 13 325 334 1:STN:280:DC%2BD3Mrgs1Sgtw%3D%3D 10.1097/00001622-200109000-00003 11555708 (Pubitemid 32783410)
4. B Coiffier 2007 Rituximab therapy in malignant lymphoma Oncogene 26 3603 3613 1:CAS:528:DC%2BD2sXlslCqsbs%3D 10.1038/sj.onc.1210376 17530014 (Pubitemid 46844778)
5. AA Alizadeh MB Eisen RE Davis, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503 511 1:CAS:528:DC%2BD3cXht1Shtrg%3D 10.1038/35000501 10676951 (Pubitemid 30082188)
6. CP Hans DD Weisenburger TC Greiner, et al. 2004 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 275 282 1:CAS:528:DC%2BD2cXhsFGhsA%3D%3D 10.1182/blood-2003-05-1545 14504078 (Pubitemid 38029949)
7. G Gao X Liang J Jiang, et al. 2009 A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma Acta Oncol 49 1 11 1:CAS:528:DC%2BD1MXotFGktb4%3D 10.1080/02841860903150502
8. G Lenz G Wright S Dave, et al. 2007 Gene expression signatures predict overall survial in diffuse large B cell lymphoma treated with rituximab and chop-like chemotherapy Blood 110 209a ASH Annual Meeting Abstracts 348
9. Y Xia ZM Li YX Shi ZJ Xia WQ Jiang HQ Huang 2009 Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma Chin J Cancer 28 146 149
10. WH Wilson K Dunleavy S Pittaluga, et al. 2008 Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers J Clin Oncol 26 2717 2724 1:CAS:528:DC%2BD1cXnvVOhsbo%3D 10.1200/JCO.2007.13.1391 18378569
11. ZG Xia ZZ Xu WL Zhao, et al. 2010 The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment Ann Hematol 89 171 177 1:CAS:528:DC%2BC3cXjt1yltg%3D%3D 10.1007/s00277-009-0799-2 19669764
12. H Nyman M Adde ML Karjalainen-Lindsberg, et al. 2007 Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood 109 4930 4935 1:CAS:528:DC%2BD2sXmt1Ogu7Y%3D 10.1182/blood-2006-09-047068 17299093 (Pubitemid 46827791)
13. ME Falagas DK Matthaiou IA Bliziotis 2006 The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials J Antimicrob Chemother 57 639 647 1:CAS:528:DC%2BD28Xis1Glu74%3D 10.1093/jac/dkl044 16501057
14. BD Cheson B Pfistner ME Juweid, et al. 2007 Revised response criteria for malignant lymphoma J Clin Oncol 25 579 586 10.1200/JCO.2006.09.2403 17242396 (Pubitemid 350002966)
15. B Saito E Shiozawa T Usui, et al. 2007 Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma Leukemia 21 2563 2566 1:CAS:528:DC%2BD2sXhtlaksr7L 10.1038/sj.leu. 2404844 17597802 (Pubitemid 350148910)
16. K Fu DD Weisenburger WWL Choi, et al. 2008 Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma J Clin Oncol 26 4587 4594 1:CAS:528:DC%2BD1cXht1KqtLfI 10.1200/JCO.2007.15.9277 18662967
17. A Rosenwald G Wright WC Chan, et al. 2002 The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 346 1937 1947 10.1056/NEJMoa012914 12075054 (Pubitemid 34651353)
18. BD Cheson 2006 Monoclonal antibody therapy for B-cell malignancies Semin Oncol 33 S2 S14 1:CAS:528:DC%2BD28XmtlKit74%3D 10.1053/j.seminoncol.2006.01.024 16720198 (Pubitemid 44251035)
19. C Stolz M Schuler 2009 Molecular mechanisms of resistance to rituximab and pharmacologic strategies for its circumvention Leuk Lymphoma 50 873 885 1:CAS:528:DC%2BD1MXntFChs7c%3D 10.1080/10428190902878471 19373595
20. SP Hilchey O Hyrien TR Mosmann, et al. 2009 Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab Blood 113 3809 3812 1:CAS:528:DC%2BD1MXlt1yjsb0%3D 10.1182/blood-2008-10-185280 19196657
21. AR Jazirehi S Huerta-Yepez G Cheng B Bonavida 2005 Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis Cancer Res 65 264 276 1:CAS:528:DC%2BD2MXhvFamsQ%3D%3D 15665303
22. RE Davis KD Brown U Siebenlist LM Staudt 2001 Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells J Exp Med 194 1861 1874 1:CAS:528:DC%2BD38Xpt1ar 10.1084/jem.194.12.1861 11748286 (Pubitemid 34028664)
23. J Iqbal VT Neppalli G Wright, et al. 2006 BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma J Clin Oncol 24 961 968 1:CAS:528:DC%2BD28Xitl2qt7s%3D 10.1200/JCO.2005.03.4264 16418494 (Pubitemid 46638851)
24. L He J Thomson M Hemann, et al. 2005 A microRNA polycistron as a potential human oncogene Nature 435 828 833 1:CAS:528:DC%2BD2MXkvVGgs70%3D 10.1038/nature03552 15944707 (Pubitemid 40839734)
25. CZ Chen 2005 MicroRNAs as oncogenes and tumor suppressors N Engl J Med 353 1768 1771 1:CAS:528:DC%2BD2MXhtFKrtLjK 10.1056/NEJMp058190 16251533 (Pubitemid 41549888)
26. CH Lawrie S Soneji T Marafioti, et al. 2007 MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma Int J Cancer 121 1156 1161 1:CAS:528:DC%2BD2sXhtFGhu7nP 10.1002/ijc.22800 17487835 (Pubitemid 47101656)
27. CH Lawrie S Gal HM Dunlop, et al. 2008 Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma Br J Haematol 141 672 675 10.1111/j.1365-2141.2008.07077.x 18318758 (Pubitemid 351667616)
28. CH Lawrie J Chi S Taylor, et al. 2009 Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma J Cell Mol Med 13 1248 1260 1:CAS:528:DC%2BD1MXhtFCku7nE 10.1111/j.1582-4934.2008.00628.x 19413891